Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Treatment of Asian Flushing Syndrome With Topical Alpha Agonists

Trial Profile

Treatment of Asian Flushing Syndrome With Topical Alpha Agonists

Status: Completed
Phase of Trial: Phase 0

Latest Information Update: 04 Dec 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Brimonidine (Primary)
  • Indications Erythema; Flushing
  • Focus Therapeutic Use
  • Most Recent Events

    • 04 Dec 2019 Primary endpoint (Patient Erythema Self Assessment) has been met, according to the results published in the JAMA Dermatology.
    • 04 Dec 2019 Primary endpoint (Clinician Erythema Score) has been met, according to the results published in the JAMA Dermatology.
    • 04 Dec 2019 Results (n=20) published in the JAMA Dermatology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top